Loading stock data…
Upstream Bio (UPB)
$6.70-0.05 (-0.81%)
Market OpenUpdated 3:01 PM EDT
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Upstream Bio, Inc. in the Healthcare sector is trading at $6.70 with a market capitalization of $324M. Wall Street consensus targets $38.25 (8 analysts), implying a +471.3% move over the next 12 months. The stock is currently near its 52-week low of $5.85, remaining 61.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +471.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.03M↑ | $668,000↓ | $683,000↓ | $937,000↑ | $566,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$43.62M↑ | -$46.17M↓ | -$37.83M↑ | -$44.35M↓ | -$32.01M |
| Net Income | -$40.59M↑ | -$42.46M↓ | -$33.75M↑ | -$39.97M↓ | -$27.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$324.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-51.57%
Volume
Today's trading volume
422,069
Recent News
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Upstream Bio, Inc. (NASDAQ:UPB) is one of the most promising stocks on our list. TheFly reported on June 3 that H.C. Wainwright analyst Matthew Caufield initiated coverage of UPB with a Buy rating and a $36 price target. The […]
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?
Upstream Bio, Inc. (NASDAQ:UPB) is among the best low priced stocks to get rich in 2026. On June 12, JPMorgan significantly trimmed the price target on Upstream Bio, Inc. (NASDAQ:UPB) to $8 from $35, while downgrading the stock from Overweight to Neutral. In a research note, the analyst said that other peers in asthma are […]
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls
Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and the price of oil on any given day. Those two items have dictated the direction of stocks, bonds, precious metals, and crypto since ... Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More